Stanislaw R Burzynski

Summary

Affiliation: Burzynski Clinic
Country: USA

Publications

  1. ncbi Gene silencing--a new theory of aging
    Stanislaw R Burzynski
    Burzynski Clinic, Houston, TX 77055, USA
    Med Hypotheses 60:578-83. 2003
  2. ncbi Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas, USA
    Drugs R D 4:91-101. 2003
  3. ncbi The present state of antineoplaston research (1)
    Stanislaw R Burzynski
    Burzynski Research Institute, Houston, TX 77055, USA
    Integr Cancer Ther 3:47-58. 2004
  4. ncbi Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77082, USA
    Integr Cancer Ther 3:257-61. 2004
  5. ncbi Aging: gene silencing or gene activation?
    Stanislaw R Burzynski
    Burzynski Clinic, 9432 Old Katy Road, Houston, TX 77055, USA
    Med Hypotheses 64:201-8. 2005
  6. ncbi Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77055, USA
    Drugs R D 5:315-26. 2004
  7. ncbi Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, TX 77055, USA
    Integr Cancer Ther 4:168-77. 2005
  8. ncbi Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77055, USA
    Integr Cancer Ther 5:40-7. 2006
  9. ncbi Treatments for astrocytic tumors in children: current and emerging strategies
    Stanislaw R Burzynski
    Burzynski Clinic, Houston, Texas, USA
    Paediatr Drugs 8:167-78. 2006

Detail Information

Publications9

  1. ncbi Gene silencing--a new theory of aging
    Stanislaw R Burzynski
    Burzynski Clinic, Houston, TX 77055, USA
    Med Hypotheses 60:578-83. 2003
    ....
  2. ncbi Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas, USA
    Drugs R D 4:91-101. 2003
    ..A phase II study of antineoplaston A10 and AS2-1 was conducted to evaluate the antineoplastic activity in patients with recurrent diffuse intrinsic brain stem glioma...
  3. ncbi The present state of antineoplaston research (1)
    Stanislaw R Burzynski
    Burzynski Research Institute, Houston, TX 77055, USA
    Integr Cancer Ther 3:47-58. 2004
    ..Gene array studies will explain antineoplaston-induced changes in gene expression...
  4. ncbi Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77082, USA
    Integr Cancer Ther 3:257-61. 2004
    ....
  5. ncbi Aging: gene silencing or gene activation?
    Stanislaw R Burzynski
    Burzynski Clinic, 9432 Old Katy Road, Houston, TX 77055, USA
    Med Hypotheses 64:201-8. 2005
    ..The application of DNA microarray techniques to human studies should provide more information about differences in gene expression in different age groups and help design more effective age management regimens...
  6. ncbi Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77055, USA
    Drugs R D 5:315-26. 2004
    ..To evaluate the response rates, survival and toxicity of treatment with antineoplaston A10 and AS2-1 (ANP) in the first 12 children enrolled in our studies diagnosed with incurable recurrent and progressive multicentric glioma...
  7. ncbi Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, TX 77055, USA
    Integr Cancer Ther 4:168-77. 2005
    ....
  8. ncbi Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma
    Stanislaw R Burzynski
    Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77055, USA
    Integr Cancer Ther 5:40-7. 2006
    ..Fourteen patients had diffuse intrinsic tumors. Twelve patients suffered from recurrence, and 6 patients did not have radiation therapy or chemotherapy...
  9. ncbi Treatments for astrocytic tumors in children: current and emerging strategies
    Stanislaw R Burzynski
    Burzynski Clinic, Houston, Texas, USA
    Paediatr Drugs 8:167-78. 2006
    ..Improvement of quality of life is an equally important objective of treatment. Radiation therapy and chemotherapy result in serious late toxicities...